Overview of Shares and Voting Rights
As of the most recent reports, Innate Pharma S.A. has provided details on its outstanding shares and voting rights. This information is crucial for understanding the structure of shareholder voting and the governance of the company.
Total Number of Shares Outstanding
Innate Pharma has a total of 83,830,336 ordinary shares outstanding. In addition, there are 6,494 Preferred Shares from 2016 and 7,581 Preferred Shares from 2017. These figures represent the total equity spread among shareholders.
Understanding Voting Rights
Innate Pharma calculates its voting rights in two ways: the total number of theoretical voting rights and the total number of exercisable voting rights. The theoretical voting rights sum to 84,585,576, which includes all shares, even those with suspended voting rights. In contrast, the number of exercisable voting rights is 84,567,001, which excludes treasury shares.
Regulatory Compliance
The reporting of shares and voting rights complies with French regulations, specifically fulfilling obligations set out in the Code de Commerce and AMF General Regulation. This ensures transparency and informs the market about the company's governance structure.
About Innate Pharma
Innate Pharma S.A. is a dynamic biotechnology firm that is advancing immunotherapy solutions dedicated to cancer treatment. The company focuses on harnessing the body's innate immune system through multiple therapeutic strategies. Its proprietary platform, known for multi-specific NK Cell Engagers, as well as Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs), exemplifies its innovative approach to treating various tumor types.
Among its notable drug development initiatives, Innate is advancing several ANKET candidates and IPH4502, aimed at solid tumors. The company is also collaborating with AstraZeneca to develop anti-NKG2A mAb monalizumab targeted at non-small cell lung cancer and has made significant contributions to therapies addressing cutaneous as well as peripheral T cell lymphomas.
Strategic Partnerships
Partnerships with leading biopharmaceutical companies such as Sanofi and AstraZeneca complement Innate Pharma's research efforts. Collaborations with renowned research institutions help accelerate innovation and broaden the impact of Innate's research and development, benefiting patients who rely on effective cancer therapies.
Company Headquarters and Contact
Innate Pharma is headquartered in Marseille, France, with an additional office located in Rockville, MD, USA. This bi-national presence enables the company to leverage key markets effectively while engaging with global research and development initiatives.
Information About Innate Pharma Shares
As a publicly traded entity, Innate Pharma is listed on Euronext Paris and NASDAQ as IPH and IPHA, respectively. The company's ISIN code is FR0010331421, further facilitating transparency and making it easier for investors to track its shares.
Frequently Asked Questions
What is the total number of shares outstanding for Innate Pharma?
As of the latest report, Innate Pharma has 83,830,336 ordinary shares outstanding.
How many voting rights does Innate Pharma have?
Innate Pharma has a total of 84,585,576 theoretical voting rights and 84,567,001 exercisable voting rights.
What types of shares does Innate Pharma issue?
Innate Pharma issues ordinary shares as well as Preferred Shares from 2016 and 2017.
Where is Innate Pharma headquartered?
Innate Pharma is headquartered in Marseille, France, with an additional office in Rockville, MD, USA.
What stock exchanges list Innate Pharma?
Innate Pharma is listed on Euronext Paris and NASDAQ with the ticker symbols IPH and IPHA, respectively.
